Previous 10 | Next 10 |
Vaxart (VXRT) may have seen over a thirteen-fold rise in share price over the past 12-month period thanks to its COVID-19 vaccine development. That meteoric rise has not discouraged the analysts to issue bullish views on the stock despite two COVID-19 vaccine candidates receiving conditional ...
Multiple biotechs have coronavirus vaccines with regulatory authorizations, and others are about to cross the finish line . But investors should still keep an eye on the early-stage companies, such as Inovio (NASDAQ: INO) and Vaxart (NASDAQ: VXRT) . In this video from ...
Vaxart (NASDAQ: VXRT) had an amazing run in 2020. The tiny biotech started off the year as a micro-cap stock, but when the COVID-19 pandemic struck, it -- like many vaccine-related stocks -- took off. Vaxart jumped out of obscurity and delivered one of the market's top performances ...
Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) will almost certainly enjoy huge revenue growth this year. Their respective coronavirus vaccines have already been given to millions of people in the U.S. and other countries. Billions of dollars will soon flow into the drugmaker...
Vaxart (NASDAQ: VXRT) isn't as well-known as other coronavirus vaccine makers. However, the small biotech stock emerged as a huge winner in 2020. Vaxart is currently evaluating its tablet COVID-19 vaccine in an early stage clinical study. In this Motley Fool Live video recorded ...
While much of the discussion around COVID-19 vaccines has lately focused on the difficulties of shipping and storing them at temperatures that would make a polar bear shiver, Vaxart (NASDAQ: VXRT) has been steadily working on developing one that would eliminate a lot of the logistic...
This article reviews the Value & Momentum Breakouts 2020 trading year and addresses new strategies, models, and enhancements for 2021. 10 different model portfolios beat the S&P 500 in 2020 and six of these methods have beaten the S&P 500 consistently the past several year...
How did your investments perform in 2020? Hopefully, quite well. Last year turned out to be an easy one for investors to make money. The S&P 500 index jumped 16%. If you bought stocks during the market meltdown in March or shortly afterward, you could have enjoyed exceptionally ...
Moderna and Pfizer were first to market with their coronavirus vaccines. The U.S. Food and Drug Administration (FDA) granted them both Emergency Use Authorization (EUA) last month. But that doesn't mean the vaccine race is over. Considering global demand, there is plenty of room for...
Shares of Vaxart (NASDAQ: VXRT) tumbled 28.5% in December, according to data provided by S&P Global Market Intelligence , as investors continued to take stock of its oral COVID-19 vaccine. The biotech rocketed to stratospheric heights earlier in the year on the promise t...
News, Short Squeeze, Breakout and More Instantly...
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2024 after the market close on Thursd...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...